The ASCO Post Podcast: Recent Episodes
Harborside
This week, we’re hearing from three experts on recent data focusing on the surgical management of breast cancer. All three speakers presented these findings at the 2023 Society of Surgical Oncology International Conference on Surgical Cancer Care, which took place at the end of March in Boston.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we present reports on four important presentations made during the American Association for Cancer Research (AACR) Annual Meeting, focusing on novel inhibitory therapeutics; adjuvant immunotherapy for patients with hepatocellular carcinoma at high risk of recurrence; the effect of treatment protocols guided by precision medicine on survival for patients with relapsed or refractory cancer; and community engagement for clinical trial recruitment.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we are sharing news presented during the American Association for Cancer Research (AACR) Annual Meeting, which was held earlier this month in Orlando. We feature three researchers discussing their findings in non–small cell lung cancer, early-stage breast cancer, and solid tumors harboring DNA damage response alterations.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The National Comprehensive Cancer Network, or NCCN, held its annual meeting recently in Orlando. On this week’s episode of The ASCO Post podcast, we’ll hear from two presenters who discussed quality of life issues in individuals with cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The National Comprehensive Cancer Network, or NCCN, held its annual meeting recently in Orlando. On this week’s episode, we’ll hear from two of the presenters who discussed NCCN Clinical Practice Guidelines Updates in chronic lymphocytic leukemia/small lymphocytic lymphoma and CNS cancers in adults. We’ll also hear about a third presentation on the molecular landscape of metastatic colorectal cancer and its treatment.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we discuss two important studies presented over the past month at two oncology meetings, including the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer and the Miami Breast Cancer Conference.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we discuss two studies that were presented at the Society of Surgical Oncology (SSO) 2023 International Conference on Surgical Cancer Care. First, we’ll share results of the SWOGS1512 study of neoadjuvant pembrolizumab in patients with stage II to III desmoplastic melanoma. Then, we'll hear about a study which aimed to evaluate whether personalized ctDNA profiling could aid in identifying recurrence in patients with soft-tissue sarcomas.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we are recognizing colorectal cancer awareness month with two news items pertaining to gastrointestinal oncology reported over the past week.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this week’s episode, we’re continuing our coverage of data presented at the 2023 ASCO Genitourinary Cancers Symposium in San Francisco. Daniel Petrylak, MD, and Matt Galsky, MD, discuss two separate studies in urothelial carcinoma.
Following this, in recognition of International Women’s Day, we’ll hear from Isabel Rubio, MD, PhD, President of the European Society of Surgical Oncology. Dr. Rubio shares some of the efforts being made by the Society to help encourage women to pursue a career in surgical oncology as well as leadership roles in oncology.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’re continuing our coverage of data presented at the 2023 ASCO Genitourinary Cancers Symposium, which took place recently in San Francisco. We’ll hear from three researchers about their findings in prostate cancer trials reported at the meeting.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’re sharing news from our coverage of data presented at the 2023 ASCO Genitourinary Cancers Symposium, which took place recently in San Francisco. We’ll hear from two researchers about their findings in renal cell carcinoma (RCC).
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’re reviewing two recent U.S. Food and Drug Administration (FDA) approvals for patients with breast cancer: the February 3 approval of sacituzumab govitecan-hziy, and the January 27 approval of elacestrant.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The 2023 ASCO Gastrointestinal Cancers Symposium took place from January 19 to 21 in San Francisco. On this episode, we’re hearing from the presenting authors of three studies reported at that meeting—the SUNLIGHT, SPOTLIGHT, and NAPOLI-3 trials—which examined novel regimens in colorectal cancer, gastric cancer, and pancreatic cancer, respectively.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, Chandrakanth Are, MBBS, MBA, FSSO, FRCS, FACS, Professor of Surgical Oncology and Global Health at University of Nebraska Medical Center, and an editorial advisor for The ASCO Post,holds a conversation with John H. Strickler, MD, a medical oncologist at Duke University Medical Center. The topic is the safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated patients with KRAS G12C–mutated pancreatic cancer, based on Strickler et al’s paper published on January 5th in The New England Journal of Medicine.
Coverage of stories discussed this week on ascopost.com:
Sotorasib in Previously Treated Patients With KRAS G12C–Mutated Advanced Pancreatic Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’re continuing our coverage of research presented at the 2022 ASH Annual Meeting and Exposition. Today, we’ll hear from several researchers about their findings in lymphoma.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’re continuing our coverage of research presented at the 2022 ASH Annual Meeting and Exposition. Today, we’ll hear from several researchers about their findings in multiple myeloma.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’re featuring authors discussing their impactful research presented at the 2022 ASH Annual Meeting and Exposition, focusing on findings in different subtypes of leukemia.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This year’s San Antonio Breast Cancer Symposium took place last week. On this episode, we’re hearing from the authors of three high-impact studies that were presented at the meeting.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’re reviewing U.S. Food and Drug Administration (FDA) approvals in oncology and hematology that occurred during the month of November.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’re hearing from three authors of high-impact research that was presented at the recent Annual Meeting of the Society for Immunotherapy of Cancer, or SITC. Their studies focused on immune checkpoint inhibitors for patients living with HIV and cancer, T-cell receptor T-cell therapy for patients with solid tumors, and radiation boosts plus pembrolizumab in patients with triple-negative breast cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’re hearing from authors of recent impactful research in the field of genitourinary oncology.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’re covering two recent approvals from the U.S. Food and Drug Administration (FDA): one in unresectable hepatocellular carcinoma, and one in relapsed or refractory multiple myeloma.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’re covering two studies that focused on the effects of mortgage discrimination on cancer care outcomes. The research—in colon and lung cancers—was presented during the 2022 ASCO Quality Care Symposium.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’re highlighting speakers who presented data in skin cancers during the ESMO Congress 2022, including findings on tumor-infiltrating lymphocyte therapy in advanced melanoma, cemiplimab in cutaneous squamous cell carcinoma, and the association of circulating tumor DNA and disease recurrence in patients with later-stage melanoma.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The 2022 ASCO Quality Care Symposium took place in Chicago over the weekend. On this episode, we’re featuring two speakers who presented data at the meeting: the first focuses on the effects of Medicaid expansion on cancer mortality rates, and the second describes efforts to improve prescribing practices for prophylactic colony stimulating factors in the treatment of neutropenia.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’re highlighting speakers who presented data in breast cancer during the ESMO Congress 2022. The first speaker discusses patterns of genomic instability in metastatic breast cancer, and the second touches on oncofertility care for young patients with breast cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The ESMO Congress 2022 took place in Paris from September 9 to 13. In this episode, we highlight key research presented at the meeting. We’ll first hear from the presenting author of Abstract LBA1 on the effect of air pollutants on the risk of non–small cell lung cancer. Then, we’ll hear from a researcher on the SWOG S1801 team on the benefits of different therapeutic strategies using pembrolizumab in patients with advanced melanoma. Finally, we’ll hear about the results of the IMmotion 010 study of adjuvant atezolizumab for renal cell carcinoma post-nephrectomy.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’re covering the FDA approval of pemigatinib for patients with myeloid or lymphoid neoplasms and an FGFR1 rearrangement. We’ll also discuss a long-term update from the STAMPEDE trial of radiotherapy in prostate cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Pemigatinib for Patients With Myeloid/Lymphoid Neoplasms and FGFR1 Rearrangement
Long-Term Benefit of Radiotherapy Confirmed in Advanced Prostate Cancer: STAMPEDE Trial Follow-up
To listen to more podcasts from ASCO, visit asco.org/podcasts.
In this episode, we’re featuring two speakers presenting data from the European Hematology Association 2022 Congress, focusing on findings in acute myeloid leukemia and diffuse large B-cell lymphoma.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’re featuring discussions about data in colorectal cancer that were presented at the 2022 ASCO Annual Meeting. Dr. Michael Overman, of The University of Texas MD Anderson Cancer Center, speaks with two presenters about guiding therapy with circulating tumor DNA and refining treatment strategies for RAS wild-type metastatic disease.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
Dr. Courtney DiNardo, of The University of Texas MD Anderson Cancer Center, sat down with two colleagues at the 2022 ASCO Annual Meeting to discuss data presented in leukemia. On this episode of the podcast, we’re featuring Dr. DiNardo’s conversations.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’re featuring discussions on lung cancer that took place at the 2022 ASCO Annual Meeting. They were led by Dr. Gilberto de Lima Lopes, Jr, of the Sylvester Comprehensive Cancer Center at the University of Miami. The first focuses on data from a study of a novel bispecific antibody in patients with non–small cell lung cancer that exhibits the MET exon 14 skipping mutation. The second focuses on an analysis of patients with lung cancer treated with chemoimmunotherapy regimens.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
At the 2022 ASCO Annual Meeting, Dr. Ann Partridge, of Dana-Farber Cancer Institute, discussed trends in breast cancer with several colleagues. On this episode, we’re featuring two of those conversations: one on antibody-drug conjugates, and another on endocrine therapy plus ribociclib for progressive breast cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
In this episode, we’re featuring two conversations focusing on gynecologic oncology, both led by Dr. Ursula Matulonis, of Dana-Farber Cancer Institute. Dr. Matulonis, along with two colleagues, reviews data presented at the 2022 ASCO Annual Meeting in ovarian, primary peritoneal, and fallopian tube cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
In this episode, we’re featuring two conversations from leaders in the field of genitourinary oncology. These discussions go over long-term findings in prostate cancer and urothelial carcinoma, and were both presented at the 2022 ASCO Annual Meeting.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
In this episode, we continue to highlight research presented at the 2022 ASCO Annual Meeting. We’ll first hear a discussion between two researchers on Plenary Abstract LBA1, which may establish a standard first-line combination regimen for patients with RAS wild-type and left-sided metastatic colorectal cancer. Then, we’ll hear about a study that highlighted the need to increase participation in clinical trials amongst Black women with metastatic breast cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
In this episode, we’ll hear about results from the phase III DETERMINATION trial in multiple myeloma, and a study that sought to determine when radiotherapy may be avoided after breast-conserving surgery.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’re reviewing two studies, including one plenary presentation, presented at the 2022 ASCO Annual Meeting.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’re continuing our coverage of high-impact research presented at the 2022 ASCO Annual Meeting, focusing on major studies in breast cancer and mantle cell lymphoma.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The 2022 ASCO Annual Meeting took place last week in Chicago. This week, we’re featuring conversations on two high-profile studies in breast cancer and colon cancer presented at the meeting.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
Last week, the FDA approved treatments for esophageal cancer and follicular lymphoma. On this episode, we’ll review the data supporting those approvals and hear from researchers involved in the trials investigating the efficacy of these regimens.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Two Nivolumab-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
FDA Approves Tisagenlecleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’re covering the FDA approval of a doublet therapy in certain populations of patients with newly diagnosed acute myeloid leukemia. Then we’ll hear about a comparison study of treatments for patients with metastatic breast cancer and brain metastases.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Ivosidenib/Azacitidine for Certain Patients With Newly Diagnosed AML
Etirinotecan Pegol vs Physician’s Choice of Chemotherapy for Patients With Metastatic Breast Cancer and Brain Metastases
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The Society of Gynecologic Oncology Annual Meeting on Women’s Cancer was held recently in Phoenix, Arizona. On this episode, we’ll hear from two researchers who presented data at the meeting on ovarian and cervical cancers.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’ll be discussing an updated overall survival analysis from the MONALEESA-3 trial presented at the ESMO Breast Cancer Congress 2022. Then, we’ll hear from a researcher about the current state of cancer research and anticipated trends in the field.
Coverage of stories discussed this week on ascopost.com:
Updated Overall Survival Results From MONALEESA-3 Show Improved Overall Survival in Patients With HR-Positive/HER2-Negative Breast Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On May 4, the FDA approved fam-trastuzumab deruxtecan-nxki for pretreated adult patients with unresectable or metastatic HER2-positive breast cancer. We highlight findings from the DESTINY-Breast03 trial that led to the regular approval, and also hear from Dr. Sara Hurvitz, of the University of California, Los Angeles Jonsson Comprehensive Cancer Center, who discussed the trial results with The ASCO Post at the 2021 San Antonio Breast Cancer Symposium.
Coverage of stories discussed this week on ascopost.com:
FDA Grants Regular Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Breast Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’ll continue our coverage of the American Association for Cancer Research, or AACR, Annual Meeting. We’ll hear from three specialists on the future of cancer research and treatment; the development of novel therapeutic strategies to target DNA damage response; and an overview of the FDA’s accelerated approval program.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The American Association for Cancer Research, or AACR, Annual Meeting took place from April 8 to 13 in New Orleans. The AACR Annual Meeting brings together the cancer research community to share the latest advances in cancer science and medicine, from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy. On this episode of the podcast, we’ll hear from three researchers who presented data at the meeting.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The NCCN 2022 Annual Conference took place from March 30 to April 1 as a virtual event. Designed to meet the educational needs of the interprofessional oncology care team, the conference offered more than 30 educational sessions featuring the latest advances and experts in oncology care. On this episode of the podcast, we’ll hear from three speakers who discussed recent advances in cancer care in their respective fields.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
In this week’s episode, we are discussing two recent FDA approvals—one for prostate cancer, and the other for endometrial cancer. The radioconjugate lutetium Lu-177 vipivotide tetraxetan was approved for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. Pembrolizumab was approved as a single agent for patients with advanced endometrial carcinoma that is microsatellite instability–high or mismatch repair–deficient as determined by an FDA-approved test; eligible patients have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Radioligand for Metastatic Castration-Resistant Prostate Cancer
FDA Approves Pembrolizumab for Advanced Endometrial Carcinoma
To listen to more podcasts from ASCO, visit asco.org/podcasts.
In this week’s episode, we’ll discuss a recent FDA approval in germline BRCA-mutated, HER2-negative, high-risk early breast cancer. Then, we’ll hear about the publication of final overall survival results from the MONALEESA-2 trial, which evaluated the efficacy of the addition of ribociclib to letrozole in the first-line treatment of postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast Cancer
Final Overall Survival Analysis of MONALEESA-2: Addition of Ribociclib to Letrozole in Postmenopausal Women With HR-Positive, HER2-Negative Advanced Breast Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.
In this week’s episode, we’ll discuss a recent U.S. Food and Drug Administration (FDA) approval in the early-stage non–small cell lung cancer setting. Then, we’ll hear about a study presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium that investigated methods for the de-escalation of radiation therapy for oropharyngeal cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Neoadjuvant Nivolumab and Platinum Doublet Chemotherapy for Early-Stage NSCLC
Midtreatment Imaging De-escalates Therapy for Half of Patients With Oropharyngeal Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The 2022 Multidisciplinary Head and Neck Cancers Symposium took place from February 24 to 26 in Phoenix, Arizona. The meeting provided the most up-to-date information on multidisciplinary therapies, clinical research, treatment strategies, supportive care, and scientific breakthroughs in head and neck cancer. On this episode of the podcast, we’ll hear from three authors who presented their research at the meeting.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
In this episode, we’re highlighting three presentations from the ASCO Genitourinary Cancers Symposium, held recently in San Francisco.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The 2022 ASCO Genitourinary Cancers Symposium kicked off this week. On this episode, we’ll hear about two studies presented at the meeting: one, focused on a genetic risk score that may aid in identifying men with high vs low lifetime risks of developing metastatic prostate cancer or dying from prostate cancer; and the second, about a trial that tested the efficacy of combination immunotherapy and tyrosine kinase inhibitor therapy for renal cell carcinoma.
Coverage of stories discussed this week on ascopost.com:
Comprehensive Genetic Risk Score May Predict Risk of Developing Metastatic Prostate Cancer or Death From Prostate Cancer Across Diverse Populations
To listen to more podcasts from ASCO, visit asco.org/podcasts.
In this episode, we’ll review a report on the KRYSTAL-1 trial of adagrasib therapy in various gastrointestinal cancers, and highlight key points from the newly released AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care.
Coverage of stories discussed this week on ascopost.com:
KRYSTAL-1: Adagrasib Controls Disease in Gastrointestinal Malignancies Beyond Colorectal Cancer
AACR Releases Report on the Impact of COVID-19 on Cancer Research and Patient Care
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we're reviewing a statement issued by the White House earlier this week on the Cancer Moonshot initiative.
Coverage of stories discussed this week on ascopost.com:
President Biden Reignites Cancer Moonshot
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’ll be talking about an FDA approval for uveal melanoma, as well as the efficacy of PD-1 inhibition in patients with resectable liver cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Tebentafusp-tebn for the Treatment of Unresectable or Metastatic Uveal Melanoma
Neoadjuvant Cemiplimab-rwlc for Patients With Resectable Hepatocellular Carcinoma
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The 2022 ASCO Gastrointestinal Cancers Symposium took place in San Francisco from January 20 to 22. This week, we’re featuring commentary from the authors involved in two high-impact studies in hepatobiliary cancers.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’ll hear about a combination therapy that improved progression-free survival in previously untreated patients with melanoma. Then, we’ll hear about a report that looked into the effects of prior radiotherapy on the development of adverse events in patients treated with immune checkpoint inhibitors.
Coverage of stories discussed this week on ascopost.com:
Addition of Anti–LAG-3 Antibody Relatlimab to Nivolumab in Previously Untreated Patients With Advanced Melanoma
Effect of Recent Prior Radiotherapy on Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’re discussing a phase III trial that showed improved progression-free survival with VEGFR2 inhibition in certain patients with thyroid cancer. Then, we’ll hear about a report on outcomes of breakthrough COVID-19 infection among fully vaccinated patients with cancer.
Coverage of stories discussed this week on ascopost.com:
Apatinib for Advanced Radioactive Iodine–Refractory Differentiated Thyroid Cancer
Study Finds Fully Vaccinated Patients With Cancer and Breakthrough COVID-19 Infection Remain at High Risk for Severe Outcomes
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The 2021 ASH Annual Meeting & Exposition took place from December 11-14. This week, we’re highlighting two studies featured as late-breaking abstracts at the meeting.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The San Antonio Breast Cancer Symposium was held from December 7 to 10. On this episode, we’ll hear from three authors of high-impact research that was presented during the meeting.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’ll hear about a study that examined the impact of the time of day that a patient with advanced melanoma receives an immune checkpoint inhibitor infusion on overall survival. Then, we’ll hear about two recent approvals from the FDA—one in relapsed or refractory multiple myeloma, and one for identification of ovarian cancer lesions during surgery.
Coverage of stories discussed this week on ascopost.com:
Impact of Time of Day of Immune Checkpoint Inhibitor Infusion on Overall Survival in Patients With Metastatic Melanoma
FDA Approves Triplet Therapy for Previously Treated Patients With Relapsed or Refractory Multiple Myeloma
FDA Approves Pafolacianine to Help Identify Ovarian Cancer Lesions
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The Society for Immunotherapy of Cancer (or SITC) held its Annual Meeting from November 10 to November 14. This week, we’ll hear from two researchers who presented data at SITC.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The National Comprehensive Cancer Network’s 2021 Virtual Congress on Hematologic Malignancies took place from October 14 to October 16. The meeting focused on updates to the NCCN Guidelines; new, emerging, and novel therapeutic agents; advances in cancer care; and the practical management of patients with hematologic malignancies. This week, we hear from three presenters who participated in the conference.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’re reviewing research highlights in prostate cancer that were presented at the 2021 ASTRO Annual Meeting. We’ll hear from three presenting authors on the role of radiotherapy in combination with androgen-deprivation therapy, androgen suppression, and surgery.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The 2021 ASTRO Annual Meeting took place in Chicago from October 24 to October 27. This week, we’re hearing from authors of three late-breaking abstracts. The research focuses on the role of radiotherapy in HPV-associated oropharyngeal cancer, as well as in oligoprogressive lung and breast cancers.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
Recently, Dr. Govind Persad, of the University of Denver Sturm College of Law, wrote an op-ed for The ASCO Post entitled “Oncology Care Remains Under Strain in the Ongoing COVID-19 Pandemic.”
On this episode of the podcast, Dr. Persad further discusses the challenges that patients with cancer and their physicians face surrounding COVID-19, as well as some possible solutions. As hospitals and providers have coped with those in urgent need of care, the question of how to prioritize cancer treatments has come to the fore.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, the FDA approved new indications for two drugs. The first approval was for abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer who are at high risk of disease recurrence and who also have a Ki67 score of 20% or higher. The next day, the agency approved pembrolizumab in combination with chemotherapy, with or without bevacizumab, for patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’re hearing about lung cancer data from the ESMO Congress 2021—specifically, a novel tyrosine kinase inhibitor for HER2 exon 20–mutated non–small cell lung cancer, and a second-line vaccine for HLA-A2–positive disease.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we explore more findings presented during the virtual ESMO Congress 2021—specifically, data in genitourinary oncology. We’ll hear from researchers on the efficacy and safety of abiraterone acetate added to different regimens for different types of prostate cancer, as well as patient-reported quality of life with adjuvant pembrolizumab vs placebo for renal cell carcinoma.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On September 16th, the virtual ESMO Congress 2021 began. This week, we’ll hear from the authors of three influential, late-breaking studies presented at the meeting.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’re hearing about three abstracts presented during the IASLC 2021 World Conference on Lung Cancer, focusing on clinical trial enrollment during the COVID-19 pandemic, air pollution's role in lung cancer risk, and strategies for reducing barriers and improving cancer care in low-resource areas.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’re reviewing the details of Genentech’s decision to withdraw atezolizumab’s indication for metastatic triple-negative breast cancer. We’ll then hear about a systematic review and meta-analysis that provided a profile of treatment-related adverse events observed in clinical trials combining PD-1 or PD-L1 inhibitors with chemotherapy, targeted therapy, immunotherapy, and radiotherapy.
Coverage of stories discussed this week on ascopost.com:
Update on U.S. Indication for Atezolizumab in PD-L1–Positive Metastatic Triple-Negative Breast Cancer
Profile of Adverse Events Related to PD-1 and PD-L1 Inhibitor–Based Therapy
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’ll be reviewing two recent FDA approvals in the oncology space, for patients with mismatch repair–deficient, or dMMR, recurrent or advanced solid tumors, and for adult patients with cancers associated with von Hippel-Lindau (VHL) disease.
Coverage of stories discussed this week on ascopost.com:
FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Advanced Solid Tumors
FDA Approves Belzutifan for Cancers Associated With von Hippel-Lindau Disease
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’ll be discussing a study that examined rates of breakthrough COVID-19 infection in vaccinated health-care workers. Then, we’ll move on to a report that compared the efficacy of different durations of anastrozole treatment in patients with hormone receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy.
Coverage of stories discussed this week on ascopost.com:
Breakthrough COVID-19 Infection in Fully Vaccinated Health-Care Workers
Outcomes With 2 vs 5 Years of Hormone Therapy Following Adjuvant Endocrine Therapy in Postmenopausal Women With HR-Positive Breast Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’re hearing from experts presenting data on hematologic malignancies during the 2021 Pan Pacific Lymphoma Conference, which begins on August 9 and concludes on August 13.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
Recently, The ASCO Post published an article titled ‘Defining Cure in Multiple Myeloma: A Conversation With S. Vincent Rajkumar'. On this episode of the podcast, Dr. Rajkumar, of the Mayo Clinic, talks about what it means to “cure” patients, in light of the fact that multiple myeloma has been turned into a chronic disease for many people. He also describes key studies he is involved in that are investigating the subject further.
Coverage of stories discussed this week on ascopost.com:
Defining Cure in Multiple Myeloma: A Conversation With S. Vincent Rajkumar, MD
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this episode, we’re reviewing recommendations from the International Association for the Study of Lung Cancer on the use of liquid biopsy for lung cancer. We’ll also hear about a study that compared two regimens added to radiotherapy for pancreatic cancer.
Coverage of stories discussed this week on ascopost.com:
Consensus Statement From IASLC on Liquid Biopsy for Advanced NSCLC
SBRT Plus Pembrolizumab/Trametinib vs Gemcitabine in Locally Recurrent Resected Pancreatic Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’re reviewing the FDA full approval of a therapy for previously treated patients with advanced urothelial cancer. Then, we’ll hear about a trial that investigated potential mechanisms of acquired resistance to KRAS G12C inhibitors in patients with KRAS G12C–mutant cancers.
Coverage of stories discussed this week on ascopost.com:
FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or Metastatic Urothelial Cancer
Mechanisms of Acquired Resistance to KRAS G12C Inhibition in Patients With Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’re discussing the effect of a 5- vs 2-year course of zoledronate for patients with early breast cancer; a recent FDA approval in locally advanced cutaneous squamous cell carcinoma; and a study that examined how reduced time to completion of treatment in patients with breast cancer may lead to increases in survival.
Coverage of stories discussed this week on ascopost.com:
Outcomes With 5 vs 2 Years of Zoledronate Treatment Following Adjuvant Chemotherapy in Early Breast Cancer
FDA Approves Expanded Indication for Pembrolizumab in Locally Advanced Cutaneous Squamous Cell Carcinoma
Study Finds Reduced Treatment Delays for Patients With Breast Cancer May Improve Survival Rates
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we hear from authors who presented data on multiple myeloma, myelofibrosis, and leukemia at the European Hematology Association 2021 Virtual Congress.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’re focusing on new research in genitourinary cancers presented at the 2021 ASCO Annual Meeting, including renal cell carcinoma and bladder cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’re looking specifically at data on lung cancer presented during the 2021 ASCO Annual Meeting.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’re continuing our coverage of Plenary Presentations from the 2021 ASCO Annual Meeting, including research on adjuvant pembrolizumab for patients with renal cell carcinoma; novel treatment options for advanced esophageal squamous cell carcinoma; and adjuvant chemotherapy given after standard cisplatin-based chemoradiation for women with locally advanced cervical cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week marks our 100th episode of the podcast! We launched at the start of the 2019 ASCO Annual Meeting, and this week, we’re reporting major findings from the 2021 Annual Meeting, including adjuvant therapy for patients with BRCA-mutated breast cancer, LuPSMA for metastatic prostate cancer, and an update on CodeBreak100, the trial that led to the recent FDA approval of sotorasib for KRAS G12C–mutated non–small cell lung cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’re discussing the recent U.S. Preventive Services Task Force, or USPSTF, recommendation on colorectal cancer screening beginning at 45. Then, we’ll hear about a doublet regimen that produced durable responses in patients with advanced head and neck cancer. Lastly, we’ll hear about a study being presented during the ASCO Annual Meeting about a novel immunotherapy combination for advanced melanoma.
Coverage of stories discussed this week on ascopost.com:
USPSTF Issues New Recommendation Statement on Colorectal Cancer Screening
Pembrolizumab Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The 2021 ASCO Annual Meeting kicked off this week with a premeeting presscast, where data from five studies to be presented at the conference were discussed . On this podcast, we’ll hear from two authors featured in that presscast about findings in non–small cell lung cancer and the effect of Medicaid expansion on long-term survival for patients with cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
We’ll start off hearing about an analysis of 9 weeks vs 1 year of adjuvant trastuzumab for patients with early HER2-positive breast cancer. Then, we’ll review a retrospective cohort study that aimed to quantify cancer screening deficits in the United States associated with the COVID-19 pandemic.
Coverage of stories discussed this week on ascopost.com:
Long-Term Analysis of Short-HER Trial Reported: Shorter Duration of Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer
The COVID-19 Pandemic and Cancer Screening Deficits in the United States
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, The ASCO Post sat down with Dr. John Marshall, of the Lombardi Cancer Center at Georgetown University, and his wife, Liza Marshall, a former lawyer, active advocate for patients with cancer, and a breast cancer survivor.
The Marshalls are the coauthors of a new book entitled Off Our Chests: A Candid Tour Through the World of Cancer, published this week by IdeaPress Publishing and named one of the “10 Books to Read in May 2021” by The Washington Post.
Together, they discuss the impact of Liza’s breast cancer diagnosis, how it changed their view of cancer care and the way clinicians communicate, and why their book has an important message.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’ll discuss the findings of a trial that examined the efficacy of intensified therapy for patients with newly diagnosed locally advanced rectal cancer. Then, we’ll talk about the FDA’s approval of a new agent for advanced endometrial cancer.
Coverage of stories discussed this week on ascopost.com:
Addition of Neoadjuvant FOLFIRINOX to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer
FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Endometrial Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we review data on the short-term safety of the COVID-19 vaccine in patients with cancer receiving immunotherapy. We’ll also discuss a study of the monoclonal antibody tislelizumab plus chemotherapy as first-line treatment for patients with advanced squamous non–small cell lung cancer.
Coverage of stories discussed this week on ascopost.com:
Short-Term Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients Receiving Immunotherapy
First-Line Tislelizumab Plus Chemotherapy vs Chemotherapy Alone in Advanced Squamous NSCLC
To listen to more podcasts from ASCO, visit asco.org/podcasts.
On this week’s podcast, we’re continuing our coverage of the 2021 AACR Annual Meeting. We’ll hear from researchers on the role of cancer biology in treatment paradigms; novel strategies in the care of patients with brain metastases; and the influence of diet on cancer development and response to therapy.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The 2021 AACR Annual Meeting launched week 1 of a two-week program on April 10 featuring plenary sessions and major scientific symposia. Week 2 will take place in May. In this week’s podcast, The ASCO Post speaks with faculty at AACR’s annual meeting who presented clinical research in non–small cell lung cancer, non-Hodgkin lymphoma, and uveal melanoma.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’ll be discussing a recent presentation that parsed out differences in disease seen in younger vs older women with breast cancer. We’ll also hear about an update to the NCCN Guidelines for triple-negative breast cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’re again discussing findings presented during the Society of Gynecologic Oncology’s (SGO) Virtual 2021 Annual Meeting on Women’s Cancer. We’re hearing from three presenting authors on a number of topics, including maintenance olaparib for newly diagnosed advanced ovarian cancer; maintenance niraparib for platinum-sensitive ovarian cancer; and methods for reducing radiotherapy toxicity in patients with cervical cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The Society of Gynecologic Oncology’s virtual 2021 Annual Meeting on Women’s Cancer is taking place from March 19 to 25. This week, we’re hearing about findings presented at the meeting in endometrial and ovarian cancers.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
More than a year into the COVID-19 pandemic, researchers are beginning to examine the effects of the virus in the larger health-care sphere. This week, we’ll review a report on an observed increase of breast cancer diagnoses in Italy after pandemic-related screening interruptions. We’ll also discuss two FDA approvals that occurred over the past week for lymphoma and kidney cancer.
Coverage of stories discussed this week on ascopost.com:
Increase in Diagnosis of Node-Positive and Stage III Breast Cancer After Screening Interruption Due to the COVID-19 Pandemic
FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma
FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’re discussing recent regulatory decisions, ranging from FDA approvals in multiple myeloma and non–small cell lung cancer to the withdrawal of a widely used drug’s indication for small cell lung cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma
FDA Approves Lorlatinib for Metastatic ALK-Positive NSCLC
Pembrolizumab's Indication in Small Cell Lung Cancer Is Withdrawn
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’re continuing our coverage of results presented at the 2021 Genitourinary Cancers Symposium, focusing on research findings in renal cell carcinoma and bladder cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The 2021 Genitourinary Cancers Symposium took place virtually from February 11 to 13. This week, we’re hearing from three authors of novel research in bladder and kidney cancers.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’re again focusing on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic. We’ll hear about findings in mesothelioma, small cell lung cancer, and drug development.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’re hearing from two thoracic oncologists on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’ll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we’ll hear recent news about FDA oncology drug approvals in the month of January.
Coverage of stories discussed this week on ascopost.com:
Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex
FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers
FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’re back for more coverage of the 2021 Gastrointestinal Cancers Symposium, hearing about the FIGHT trial in advanced gastric/gastroesophageal junction adenocarcinoma, the ClarIDHy study in IDH1-mutated cholangiocarcinoma, and the POLO trial in BRCA-mutated pancreatic cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The 2021 Gastrointestinal Cancers Symposium, held in a virtual format this year, is being held this weekend, January 15th to 17th, 2021. We’re discussing findings from the meeting with three study authors.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’ll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We’ll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.
Coverage of stories discussed this week on ascopost.com:
Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer
Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The San Antonio Breast Cancer Symposium took place virtually from December 8 to 12th. This week, we’re featuring three important studies from the meeting, focusing on a new prognostic tool; the treatment of depression and related symptoms in young breast cancer survivors; and a chemoimmunotherapy regimen for triple-negative disease.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’ll focus further on studies presented at the 2020 ASH Annual Meeting & Exposition, including findings on the use of whole-genome sequencing to trace the origins of a blood cancer; stem cell transplant for older patients with myelodysplastic syndromes; and a triplet therapy for relapsed and refractory multiple myeloma.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
The 2020 ASH Annual Meeting & Exposition, held in a virtual format this year, begins today. We’re featuring three studies on the podcast this week from the meeting.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
As COVID-19 infection rates again spike around the nation, this week, we’re looking at two recent studies focused on COVID-19 and cancer. The first describes the rate of infection with the virus among asymptomatic patients with cancer undergoing active treatment for their solid tumors. The second explores how the ongoing pandemic is affecting the way patients with cancer choose to participate in clinical trials.
Coverage of stories discussed this week on ascopost.com:
Serial COVID-19 Screening in Asymptomatic Patients Receiving Treatment for Cancer
Survey Finds Patients With Cancer May Be Less Likely to Enroll in Clinical Trials During the COVID-19 Pandemic
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’re focusing on lung cancer—first, with a report on how therapy-related adverse events experienced by patients with lung cancer treated with immunotherapy may help to predict survival outcomes; and second, with a video about disparities in certain populations when it comes to lung cancer screening and treatment.
Coverage of stories discussed this week on ascopost.com:
Multisystem Immune-Related Adverse Events and Disease Outcomes Among Patients With NSCLC Treated With Immunotherapy
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we're focusing on high-impact research in prostate cancer presented during the virtual 2020 ASTRO Annual Meeting.
The studies included a focus on GnRH receptor antagonist therapy; imaging-based guidance for radiotherapy intensification; and methods of radiotherapy boosts.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’ll be featuring discussions of two late-breaking abstracts presented during the virtual 2020 American Society for Radiation Oncology, or ASTRO, Annual Meeting. The first focuses on the role of imaging to plan treatment with radiotherapy in patients with prostate cancer. The second discusses strategies to manage the pain of spinal metastases.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’ll focus on two recent approvals from the U.S. Food and Drug Administration in patients with leukemia and lymphoma, respectively.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Venetoclax Combination Regimen for Certain Adult Patients With AML
FDA Extends the Approval of Pembrolizumab for Patients With Classical Hodgkin Lymphoma
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’ll review results of a trial that evaluated first-line anti–PD-L1 therapy vs platinum-based chemotherapy in patients with metastatic lung cancer and high PD-L1 expression. We’ll also discuss findings from a study that evaluated whether patients receiving care for advanced cancer based on the recommendations of a molecular tumor board tended to survive longer or experience more time without disease progression.
Coverage of stories discussed this week on ascopost.com:
First-Line Atezolizumab vs Chemotherapy in PD-L1–Positive Metastatic NSCLC: IMpower110
Cancer Therapy Based on Molecular Tumor Board Recommendations: Improvement in Outcomes?
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’ll be featuring our last disease-specific roundup from the ESMO Virtual Congress 2020. We’ll hear from three experts on their findings in breast cancer, focusing on results from two IMpassion trials as well as the efficacy of a novel antibody-drug conjugate in triple-negative disease, and a telehealth program for patients receiving chemotherapy.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’ll be reviewing results from several reports on lung cancer presented during the ESMO Virtual Congress 2020. The findings focus on the use of radiotherapy, biomarkers, targeted treatments, and immunotherapy.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This week, we’re hearing about three reports on genitourinary cancers presented at ESMO Virtual Congress 2020. We’ll hear directly from the researchers about first-line treatment for metastatic renal cell carcinoma, as well as the long-term results of a doublet therapy for men with advanced hormone-naive prostate cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
This weekend, the ESMO Virtual Congress 2020 is underway, and we’re sharing interviews with two authors of high-impact papers on breast cancer and head and neck cancer presented at the event.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
We’ll discuss the efficacy of a triplet combination therapy in BRCA-mutated, HER2-negative advanced breast cancer. Then, we’ll move on to a report that detailed multiorgan immunotherapy-related adverse events in patients treated with atezolizumab. Last, we’ll review the FDA’s approval of the RET-targeted therapy pralsetinib in patients with metastatic RET fusion–positive non–small cell lung cancer.
Coverage of stories discussed this week on ascopost.com:
Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer: BROCADE3 Trial
New Study Focuses on Multiorgan Immunotherapy-Related Adverse Events in Clinical Trials
FDA Approves Pralsetinib for Metastatic RET Fusion–Positive NSCLC
To listen to more podcasts from ASCO, visit asco.org/podcasts.
Due to the unexpected passing of actor Chadwick Boseman on August 28, there has been a renewed interest in young-onset colorectal cancer. Mr. Boseman, known for his roles in Black Panther, Marshall, and Get on Up, was only 43 when he died from colon cancer. This week, we’ll go back in The ASCO Post Podcast archives and hear from Kimmie Ng, MD, MPH, who was first on the show about a year ago, offering her insights on the rising rates of colorectal cancer in young adults.
This week on The ASCO Post Podcast, we'll first hear about a study of the monoclonal antibody sintilimab in combination with pemetrexed and platinum to treat advanced nonsquamous non–small cell lung cancer. Then we'll review the results of the CheckMate 743 trial, which suggest a new standard of care in first-line treatment of unresectable malignant pleural mesothelioma.
We’ll first hear about a study that found a steep decline in non–small cell lung cancer mortality from 2013 to 2016. Then, we’ll close out with a review of a report on the addition of locoregional radiotherapy to chemotherapy in patients with chemotherapy-sensitive metastatic nasopharyngeal carcinoma.
Coverage of stories discussed this week on ascopost.com:
Study Suggests Drop in Non–Small Cell Lung Cancer Mortality Rates Due to Treatment Advances, Reduction in Incidence
Addition of Locoregional Radiotherapy to Chemotherapy for Metastatic Nasopharyngeal Carcinoma
This week, we’ll start with a follow-up analysis of pathologic complete response in patients participating in the I-SPY2 trial. Then, we’ll move on to a study that sought to answer whether a longer time from diagnosis to surgical treatment lowered overall survival in women with early-stage breast cancer. Last, we’ll hear about how the COVID-19 pandemic is worsening disparities in cancer care among racial and ethnic minorities and the medically underserved.
Coverage of stories discussed this week on ascopost.com:
Association of Pathologic Complete Response With 3-Year Outcomes in I-SPY 2 Trial of Neoadjuvant Therapy for Stage II or III Breast Cancer
Increased Time to Breast Cancer Surgery May Not Impact Overall Survival for Patients With Early-Stage Disease
This week, we’ll review recommendations from a new guideline issued by the American Cancer Society on cervical cancer screening. Then, we’ll discuss the FDA’s approval of a triplet therapy for advanced melanoma. Lastly, we’ll hear a summary of a panel discussion on telehealth for patients with cancer during the COVID-19 pandemic.
Coverage of stories discussed this week on ascopost.com:
American Cancer Society Updates Guideline for Cervical Cancer Screening
FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced BRAF V600–Mutated Melanoma
This week, we’ll discuss a study that compared two combination treatments for previously untreated patients with localized pancreatic cancer. Then, we’ll explore whether a longer-established diagnosis of cancer is associated with higher risk of severe COVID-19 infection or death from the virus. Last, we’ll review the FDA’s recent approval of a CAR T-cell immunotherapy for patients with relapsed or refractory mantle cell lymphoma.
Coverage of stories discussed this week on ascopost.com:
First-Line FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for Localized Pancreatic Cancer
Are Patients With a Longer-Established Diagnosis of Cancer at Higher Risk for More Severe Infection or Death From COVID-19?
FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma
This week, we’ll discuss phase II results on cabozantinib in patients with advanced bladder cancer. Then, we’ll review a study on behaviors related to COVID-19 prevention among cancer survivors. Lastly, we’ll hear a discussion about the keynote lecture presented at the First International Summit on Interventional Pharmacoeconomics.
Coverage of stories discussed this week on ascopost.com:
Cabozantinib in Platinum-Refractory Metastatic Urothelial Carcinoma
Cancer Survivors Are Adhering to COVID-19–Related Preventive Behaviors, but Continuity of Care May Be Impacted
This week, we’ll discuss the efficacy of the combination of lenvatinib and pembrolizumab for patients with advanced gastric cancer. We’ll also highlight key points from the recent USPSTF draft recommendation on CT screening for lung cancer. Finally, we’ll review a regulatory approval in metastatic bladder cancer and hear from the principal investigator of the confirmatory trial.
Coverage of stories discussed this week on ascopost.com:
Lenvatinib Plus Pembrolizumab for Advanced Gastric Cancer
USPSTF Issues Draft Recommendation Statement on Screening for Lung Cancer
FDA Approves Maintenance Avelumab for the Treatment of Advanced Urothelial Carcinoma
This week, we’ll review two influential breast cancer studies presented during the ASCO20 Virtual Scientific Program: MINDACT and HER2CLIMB.
This week, we’ll be hearing from the presenters of three abstracts focused on multiple myeloma presented during the ASCO20 Virtual Scientific Program.
With this week bringing record highs of COVID-19 infection across the nation, we’re revisiting two presentations from the ASCO20 Virtual Scientific Program on the effect of the virus on patients with cancer.
We're hearing from the authors of three high-impact papers on research in prostate cancer presented during the ASCO20 Virtual Scientific Program.
This week, we’ll review two late-breaking abstracts from the ASCO20 Virtual Scientific Program that reported negative results. Both were presented during the plenary program.
This week, we’ll be hearing from the authors of three late-breaking abstracts presented in the Plenary program at the ASCO20 Virtual Scientific Program. Their findings highlight significant advances in lung cancer, bladder cancer, and colorectal cancer.
In part 2 of our conversation with Dr. Syed Abutalib, Associate Director of the Hematology and Cellular Therapy Program and Director of the Clinical Apheresis Program at Cancer Treatment Centers of America, Zion, Illinois; Associate Professor at the Roseland Franklin University of Medicine and Science; and Founder and Co-Editor of Advances in Cell and Gene Therapy, Dr. Abutalib outlines methods of treatment and prevention for coagulation issues in patients with COVID-19, and summarizes the hematologic consequences of the virus.
This week, we spoke with Dr. Syed Abutalib, Associate Director of the Hematology and Cellular Therapy Program and Director of the Clinical Apheresis Program at Cancer Treatment Centers of America, Zion, Illinois; Associate Professor at the Roseland Franklin University of Medicine and Science; and Founder and Co-Editor of Advances in Cell and Gene Therapy. Dr. Abutalib outlines recent data on coagulation issues seen in patients with COVID-19.
This week, we’ll be featuring some research highlights from the AACR Virtual Annual Meeting, including data on a triplet regimen for women with high-risk, HER2-negative breast cancer; findings on immunotherapy combined with targeted therapy for patients with BRAF V600-mutated melanoma; and a paper on trends in the locations of tobacco and vape shops.
This week, we’ll start off with a report that showed that ibrutinib may help to protect patients infected with COVID-19 from pulmonary injury due to the disease. Next, we’ll move onto a report from the AACR Virtual Annual Meeting on talazoparib in patients with locally advanced or metastatic HER2-negative germline BRCA-mutated breast cancer. Lastly, we’ll review the FDA’s approval of niraparib for patients with advanced ovarian cancer.
Coverage of stories discussed this week on ascopost.com:
Potential Protective Effect of Ibrutinib Against Pulmonary Injury in Patients With COVID-19
AACR 2020: Final Overall Survival Results From the Phase III EMBRACA Trial
FDA Approves Niraparib as Maintenance Therapy for Advanced Ovarian Cancer
The U.S. Food and Drug Administration (FDA) had a very busy 10 or so days, so this week, we’ll go over five recent oncology and hematology approvals the Agency issued, in bladder cancer, breast cancer, bile duct cancer, and leukemia.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial Cancer
FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer
FDA Approves Pemigatinib for Patients With Cholangiocarcinoma and an FGFR2 Rearrangement or Fusion
FDA Approves Ibrutinib/Rituximab for CLL/SLL
FDA Approves Sacituzumab Govitecan-hziy for Patients With Previously Treated Metastatic Triple-Negative Breast Cancer
To begin this week, we’ll discuss a report that focused on the characteristics and outcomes of patients with both COVID-19 and cancer in Wuhan, China. Next, we’ll turn to a paper on the efficacy of stereotactic ablative radiotherapy in men with oligometastatic prostate cancer. Lastly, we’ll talk about the FDA’s approval of encorafenib plus cetuximab in patients with BRAF V600E–mutated colorectal cancer.
Coverage of stories discussed this week on ascopost.com:
Outcomes of COVID-19 Infection in Patients With Cancer in Wuhan, China
Stereotactic Ablative Radiation vs Observation in Oligometastatic Prostate Cancer: ORIOLE Trial
FDA Approves Encorafenib/Cetuximab for BRAFV600E–Mutated Metastatic Colorectal Cancer
We begin with an interview with Dr. William A. Wood of the University of North Carolina, Chapel Hill. Dr. Wood is current Chair of the ASH Research Collaborative’s Data Hub Oversight Group, and he spoke with us about the new COVID-19 Registry for Malignant Hematology. Next, we’ll move onto a report on the relationship between breastfeeding and reduced risk of invasive ovarian cancer. And to round out this week’s episode, we’ll go over the FDA’s approval of lustpatercept-aamt for anemia in patients with myelodysplastic syndromes.
Coverage of stories discussed this week on ascopost.com:
ASH Research Collaborative's Data Hub Creates International Data Registry for Patients With Blood Cancers and COVID-19
Does Breastfeeding Affect Invasive Ovarian Cancer Risk?
FDA Approves Luspatercept-aamt for Second-Line Treatment of Anemia in Adult Patients With Myelodysplastic Syndromes
This week, we’ll start with a report on end-of-trial findings with a triplet combination treatment for HER2-positive metastatic breast cancer. Then, we’ll hear from the director of a comprehensive cancer center on how her institution is handling the coronavirus outbreak. Lastly, we’ll discuss the FDA’s approval of durvalumab in small cell lung cancer.
Coverage of stories discussed this week on ascopost.com:
End-of-Study Results From CLEOPATRA: Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
FDA Approves Durvalumab as Part of a First-Line Combination Regimen for Extensive-Stage SCLC
To start off this week, we’ll discuss a report from physicians in Washington state about how they’re handling cancer care currently in their institutions amid the COVID-19 pandemic. We’ll then hear from Dr. Giuseppe Curigliano, who spoke with The ASCO Post from his office in Milan about how Italy is addressing the needs of patients with cancer. Lastly, we’ll go over a paper about the reintroduction of a combination regimen when disease progresses after upfront treatment in patients with colorectal cancer.
Coverage of stories discussed this week on ascopost.com:
Managing Cancer Care During the COVID-19 Pandemic
Reintroduction of FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
We're covering the topic on everyone’s minds—coronavirus. We’ll start with the state of the epidemic as it relates to patients with cancer and the preparedness of the institutions that care for them. Next, we’ll look at a study from China that examined the impact of COVID-19 on patients with cancer. Then, we’ll finish up by discussing an FDA approval of a combination therapy for patients with hepatocellular carcinoma.
Coverage of stories discussed this week on ascopost.com:
Mitigating the Spread of COVID-19 and Its Impact on Cancer
COVID-19 Infection in Patients With Cancer in China
FDA Approves Nivolumab/Ipilimumab for Pretreated Patients With Hepatocellular Carcinoma
We’ll begin this week by discussing an article that described the pulmonary pathology of the novel coronavirus, or COVID-19, which was found coincidentally in two patients undergoing surgery for lung cancer. We’ll also update you as to upcoming oncology meetings that have been cancelled due to concerns about the virus.
We’ll then turn to a report that found adjuvant gemcitabine/platinum chemotherapy was associated with improved disease-free survival vs surveillance in patients with locally advanced urothelial carcinoma of the upper urinary tract.
Finally, we’ll hear a summary of an important talk given at the recent ASCO-SITC Immuno-Oncology Symposium.
Coverage of stories discussed this week on ascopost.com:
Pulmonary Pathology of Early COVID-19 Pneumonia Identified Retrospectively in Two Patients With Lung Cancer
Adjuvant Gemcitabine/Platinum-Based Chemotherapy vs Surveillance for Upper Tract Urothelial Carcinoma: POUT Trial
This week, we’ll hear from two researchers on findings presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. We’ll also review the FDA’s approval of isatuximab-irfc as part of a triplet regimen for patients with relapsed or refractory multiple myeloma.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Isatuximab-irfc–Based Triplet Regimen for Patients With Relapsed or Refractory Multiple Myeloma
This week, we’ll be reviewing data from three influential abstracts presented at the recent 2020 Genitourinary Cancers Symposium in San Francisco—one on a novel, first-in-class, small molecule, hypoxia-inducible factor 2 alpha inhibitor for heavily pretreated patients with metastatic clear cell renal cell carcinoma; the second, on whether pembrolizumab in combination with the antibody-drug conjugate enfortumab vedotin may be an alternative option for platinum-ineligible patients with locally advanced or metastatic urothelial carcinoma; and the third, on treatment with pembrolizumab plus enzalutamide after disease progression on enzalutamide in patients with castration-resistant prostate cancer.
We’ll start off by discussing results from the I-SPY 2 trial on the efficacy of pembrolizumab plus chemotherapy in HER2-negative breast cancer. Then, we’ll move on to a report covering racial disparities in diagnostic and treatment technology as related to outcomes in patients with colorectal cancer. Lastly, we’ll review a long list of treatments for which the FDA recently granted Priority Review.
Coverage of stories discussed this week on ascopost.com:
Addition of Pembrolizumab to Neoadjuvant Chemotherapy in Early-Stage HER2-Negative Breast Cancer
Diagnostic and Treatment Technology Disparities Among Patients With Colorectal Cancer
First, we’ll discuss a Korean trial that looked at the role of H pylori infection and gastric cancer risk. Next, we’ll turn to a modeling study that examined HPV vaccination and cervical cancer incidence in low-income and lower–middle-income countries. Last this week, we’ll look at data presented at the ASCO-SITC Clinical Immuno-Oncology Symposium on reducing the risk for immune checkpoint inhibitor–associated colitis.
Coverage of stories discussed this week on ascopost.com:
Does Treating Individuals for H pylori Infection Reduce Gastric Cancer Risk in Those With a Family History of the Disease?
Modeling the Impact of HPV Vaccination and Cervical Screening on Cervical Cancer Elimination in Low-Income and Lower-Middle–Income Countries
This week, we’ll be featuring three researchers discussing findings presented at the 2020 Gastrointestinal Cancers Symposium: Dr. Scott Kopetz, of The University of Texas MD Anderson Cancer Center, discusses quality-of-life results from the BEACON CRC trial in BRAF V600E–mutated colorectal cancer; Dr. Brian Wolpin, of Dana-Farber Cancer Institute, talks about the efficacy of a blood-based screening test using cell-free DNA to identify methylation signals of hard-to-detect gastrointestinal cancers; and Dr. Zev Wainberg, of UCLA Medical Center, discusses a subset analysis of how a combined positive score in gastric and gastroesophageal junction cancers related to the efficacy of pembrolizumab in patients with PD-L1–positive disease.
Coverage of stories discussed this week on ascopost.com:
2020 GI Cancers Symposium: Patient-Reported Outcomes From IMbrave150, BEACON CRC
2020 GI Cancers Symposium: Detecting GI Tumors Using a Cell-Free DNA Test
The 2020 Gastrointestinal Cancers Symposium took place last weekend, and today, we’ll take a deeper dive into findings in pancreatic cancer and colorectal cancer. We’ll also review the FDA approval of tazemetostat in epithelioid sarcoma.
Coverage of stories discussed this week on ascopost.com:
‘Unprecedented’ Responses to Cisplatin/Gemcitabine in BRCA-Mutated Advanced Pancreatic Cancer
FDA Approves Tazemetostat for Epithelioid Sarcoma
We’ll begin with a study that focused on elevations in cancer incidence among responders to the World Trade Center site after the September 11, 2001 terrorist attacks. We’ll then turn to an analysis evaluating the effect of proton pump inhibitor use on decreased cognitive functioning among breast cancer survivors. Lastly, we’ll look at a trial that compared detection and grading of prostate cancer with a novel artificial intelligence system vs seasoned experts.
Coverage of stories discussed this week on ascopost.com:
Cancer Incidence in World Trade Center Responders to the September 11 Attacks
Does Proton Pump Inhibitor Use Affect Cognition in Breast Cancer Survivors?
Use of Artificial Intelligence for Diagnosing and Grading Prostate Cancer
We’ll start off this week by discussing results from the MEDALIST trial of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes. Then, we’ll move to a study that’s been covered a lot in the news: does the use of powder in the genital area increase a woman’s chance of ovarian cancer? Finally, we’ll cover two recent approvals from the FDA, for patients with bladder cancer and gastrointestinal stromal tumors, respectively.
Coverage of stories discussed this week on ascopost.com:
Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes
Is There an Association Between Powder Use and Risk of Ovarian Cancer?
FDA Approves PD-1 Inhibitor for BCG-Unresponsive, High-Risk Non–Muscle Invasive Bladder Cancer
FDA Approves Avapritinib for the Treatment of PDGFRA-Mutated Gastrointestinal Stromal Tumor
The FDA certainly had a busy December, and this week, we’ll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic Cancer
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer
FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer
In this episode, we’ll cover three important presentations from the San Antonio Breast Cancer Symposium. The first reports results from the HER2CLIMB trial on tucatinib, capecitabine, and trastuzumab for patients with HER2-positive metastatic breast cancer; the second discusses phase II findings on the activity of a novel HER2-targeting antibody-drug conjugate in HER2-positive metastatic breast cancer; and the third focuses on a postoperative treatment regimen for hormone receptor–positive, HER2-negative primary breast cancer.
On this episode, we hear from the authors of three high-impact abstracts presented at the 2019 ASH Annual Meeting & Exposition. The first paper investigated immunotherapy vs standard chemotherapy for pediatric B-cell acute lymphoblastic leukemia; the second focused on the efficacy of oral azacitidine for acute myeloid leukemia; and the third looked at a triplet regimen for relapsed or refractory multiple myeloma.
We’ll start with a trial focused on the sequence of therapies for metastatic, castration-resistant prostate cancer. Then, we’ll move on to an abstract presented at a recent American Heart Association meeting about the link between increased cardiovascular disease risk and increased cancer risk. Lastly, we’ll give you an update about the latest step in the confirmation process for Dr. Stephen Hahn, the oncologist nominated to be the next FDA Commissioner.
Coverage of stories discussed this week on ascopost.com:
Sequencing of Enzalutamide and Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
Cardiovascular Disease Risk May Be Associated With Cancer Risk
This week, we summarize two studies presented at the recent ESMO Asia Congress—one on a novel combination therapy for unresectable liver cancer, and the second on the activity of a Chinese-manufactured trastuzumab biosimilar. We’ll also discuss last week’s FDA approval of acalabrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma.
Coverage of stories discussed this week on ascopost.com:
ESMO Asia 2019: Combination of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma
ESMO Asia 2019: Trastuzumab Biosimilar HLX02 Shows Activity in HER2-Positive Metastatic Breast Cancer
FDA Approves Acalabrutinib for CLL/SLL as Part of Project Orbis
According to findings from a phase II trial, the combination of nivolumab and bevacizumab has shown activity in relapsed ovarian cancer—we discuss those findings reported inJAMA Oncology. Next, we’ll move on to a session from CHEST 2019 which outlined palliation techniques that may be of use to oncologists and pulmonologists in treating patients with end-stage lung cancer. Finally, we’ll discuss two recent FDA drug approvals for patients with hematologic disorders.
Coverage of stories discussed this week on ascopost.com:
Nivolumab Plus Bevacizumab in Relapsed Ovarian Cancer
What Is the Best Palliation for End-Stage Lung Cancer?
FDA Grants Accelerated Approval to Zanubrutinib for Pretreated Mantle Cell Lymphoma
FDA Approves Luspatercept-aamt for Anemia in Patients With Beta Thalassemia
The ADMIRAL trial evaluated gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia—we'll discuss recently reported overall survival results from The New England Journal of Medicine. Then, we’ll move onto findings from a pooled analysis of the relationship between lung cancer risk and high fiber and yogurt consumption. Last, we’ll talk about a recent restructuring of a key office within the FDA.
Coverage of stories discussed this week on ascopost.com:
ADMIRAL: Gilteritinib vs Chemotherapy in Relapsed or Refractory FLT3-Mutated AML
Dietary Fiber, Yogurt Consumption, and Lung Cancer Risk
FDA Office of Hematology Oncology Products Reorganizes, Renamed Office of Oncologic Diseases
This week, we’ll review an interim analysis of the CASPIAN trial, which evaluated the addition of durvalumab to etoposide plus platinum chemotherapy for extensive-stage small cell lung cancer. Then, we’ll talk about two recently issued guidelines on screening for colorectal cancer. Lastly, we’ll summarize some recent FDA approvals and announcements.
Coverage of stories discussed this week on ascopost.com:
CASPIAN Trial: Addition of Durvalumab to Platinum/Etoposide for First-Line Treatment of Extensive-Stage SCLC
Colorectal Cancer Screening With Fecal Immunochemical Testing, Sigmoidoscopy, or Colonoscopy for Patients Aged 50 to 79 Years Old
American College of Physicians Issues Guidance on Colorectal Cancer Screening for Average-Risk, Asymptomatic Adults Aged 50 to 75 Years
FDA Approves Pegfilgrastim Biosimilar
FDA Approves Niraparib for Patients With Homologous Recombination Deficiency–Positive Advanced Ovarian Cancer
FDA Approves Daratumumab Combination for Transplant-Eligible Patients With Multiple Myeloma
Stephen Hahn, MD, to Be Nominated FDA Commissioner
This week, we discuss two studies in gastrointestinal cancers presented at this year’s European Society for Medical Oncology Congress. First up, the NEOLAP trial assessed induction chemotherapy with nab-paclitaxel plus gemcitabine or sequential FOLFIRINOX followed by surgical exploration in patients with locally advanced pancreatic cancer. Next, we’ll discuss the ClarIDHy study, which examined treatment with ivosidenib in patients with advanced cholangiocarcinoma and an IDH1 mutation. We’ll hear from the lead authors of each of these studies, and we’ll also hear a discussion about the use of cabozantinib in advanced hepatocellular carcinoma, with Dr. Tim Meyer and Dr. Lorenza Rimassa, co-investigators for the CELESTIAL trial.
Coverage of stories discussed this week on ascopost.com:
ESMO 2019: High Conversion Rate With Certain Induction Chemotherapy Regimens Is Associated With Improved Overall Survival in Locally Advanced Pancreatic Cancer
ESMO 2019: Ivosidenib in IDH1-Mutated Advanced Cholangiocarcinoma
This week, we discuss two studies in genitourinary cancers presented at the ESMO Congress 2019. The CARD trial investigated treatment with cabazitaxel vs an androgen signaling–targeted inhibitor among patients with metastatic castration-resistant prostate cancer who had disease progression on docetaxel and the alternative androgen signaling–targeted inhibitor. The IMvigor130 trial focused on the efficacy and safety of atezolizumab as monotherapy or combined with platinum-based chemotherapy vs placebo plus platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma.
Coverage of stories discussed this week on ascopost.com:
ESMO 2019: Cabazitaxel vs Abiraterone or Enzalutamide in Previously Treated Metastatic Castration-Resistant Prostate Cancer
ESMO 2019: IMvigor130: Addition of Atezolizumab to Platinum-Based Chemotherapy in Advanced Urothelial Carcinoma
This week, we’ll be discussing selected breast cancer abstracts presented at the ESMO Congress 2019, including the MONALEESA-3 and MONARCH-2 studies of CDK4/6 inhibitors for advanced breast cancer; the BROCADE 3 trial of veliparib plus carboplatin and paclitaxel in some advanced BRCA-mutated breast cancers; and the KATE-2 study of atezolizumab and trastuzumab emtansine in HER2-positive breast cancer.
Coverage of stories discussed this week on ascopost.com:
ESMO 2019: BROCADE 3: Veliparib Plus Carboplatin/Paclitaxel in Patients With HER2-Negative, Germline BRCA-Mutated Advanced Breast Cancer
This week, we’ll be discussing research highlights in lung cancer presented at the ESMO Congress 2019, including the FLAURA trial of osimertinib in EGFR-mutated non–small cell lung cancer; the CheckMate 227 of nivolumab plus ipilimumab vs chemotherapy in non–small cell lung cancer with a PD-L1 expression of 1% or more; and the ASCEND-7 trial of ceritinib for ALK-positive non–small cell lung cancer that has spread to the brain.
Coverage of stories discussed this week on ascopost.com:
ESMO 2019: Overall Survival With Immunotherapy Doublet vs Chemotherapy in Advanced NSCLC
ESMO 2019: ASCEND-7: Ceritinib for Patients With ALK-Positive NSCLC Metastatic to the Brain
This week, we review two studies from a Presidential Symposium at ESMO focusing on the efficacy of PARP inhibitors in patients with newly diagnosed ovarian cancer.
Coverage of stories discussed this week on ascopost.com:
ESMO 2019: Studies Show PARP Inhibitors Improve Survival, Reduce Risk of Disease Recurrence or Death in Newly Diagnosed Ovarian Cancer
This week, we review a presentation on the benefit of daratumumab across populations with newly diagnosed multiple myeloma. We also talk about a study on racial disparities in colorectal cancer mortality. Lastly, we discuss the FDA’s recent approval of apalutamide in metastatic castration-sensitive prostate cancer.
Coverage of stories discussed this week on ascopost.com:
Tailoring Upfront Daratumumab Treatment for Some Patients With Multiple Myeloma
AACR Disparities: Mortality Rate for Colorectal Cancer Higher for Blacks Than for Whites in Major U.S. Cities
FDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancer
This week, we’ll be going over news from the ASTRO Annual Meeting, including an analysis of the effect of long-term hormonal therapy on men with low PSA levels treated with early salvage radiotherapy after radical prostatectomy and an update on the landmark PACIFIC trial in non–small cell lung cancer. We also discuss the launch of Project Orbis, which led to a joint approval from the FDA, the Australian Therapeutic Goods Administration, and Health Canada for lenvatinib in combination with pembrolizumab in the treatment of some patients with advanced endometrial carcinoma.
Coverage of stories discussed this week on ascopost.com:
ASTRO 2019: Long-Term Hormone Therapy May Increase Other-Cause Mortality in Men With Prostate Cancer Receiving Early Salvage Radiotherapy
ASTRO 2019: Patterns of Disease Progression in Patients With Unresectable Stage III NSCLC: Analysis of the PACIFIC Trial
FDA Grants Approval to Lenvatinib/Pembrolizumab in Advanced Endometrial Cancer, Announces Project Orbis
This week, we’ll be discussing findings presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer and the ASCO Quality Care Symposium, including a pooled analysis on 5-year overall survival rates in patients with previously treated non-small cell lung cancer receiving nivolumab vs docetaxel; the effect of out-of-pocket costs of tyrosine kinase inhibitors on survival in patients with lung cancer; and the relationship between participation in a clinical trial and overall survival in patients with advanced lung cancer.
Coverage of stories discussed this week on ascopost.com:
WCLC 2019: Pooled Analysis of CheckMate 017 and 057: 5-Year Outcomes With Nivolumab vs Docetaxel in Previously Treated NSCLC
2019 Quality Care: Cost of Treatment, Prior Authorization of Treatment Plans May Cause Barriers to Care
2019 Quality Care: Clinical Trial Enrollment May Be Associated With Reduced Mortality in Patients With Metastatic Lung Cancer
This week, we’ll be talking about an extended follow-up of a phase III trial that investigated first-line nivolumab and ipilimumab vs sunitinib in advanced renal cell carcinoma. Then we’ll go over a research letter that identified strong predictors of response to immune checkpoint inhibitor treatment. Lastly, we’ll review a report on e-cigarette secondhand smoke exposure experienced by middle and high school students.
Coverage of stories discussed this week on ascopost.com:
Extended Follow-up of CheckMate 214: Nivolumab/Ipilimumab vs Sunitinib as First-Line Treatment for Advanced RCC
Key Predictors of Response Rates to PD-1/PD-L1 Inhibitor Therapy Across Cancer Types
Exposure to Secondhand E-Cigarette Aerosols Increasing Among Middle and High School Students
This week, we review a pooled analysis of long-term survival rates in patients with previously treated non–small cell lung cancer treated with nivolumab. We then turn to the recently reported USPSTF recommendation on risk assessment, genetic counseling, and genetic testing for BRCA1 or BRCA2 mutations. Lastly, we discuss the recent FDA approval of entrectinib for NTRK-fusion cancers and ROS1-positive NSCLC.
Coverage of stories discussed this week on ascopost.com:
Pooled Analysis of 4-Year Survival With Nivolumab Therapy in Patients With Previously Treated Advanced NSCLC
USPSTF Recommendation on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer
FDA Approves Entrectinib for NTRK-Fusion Cancers, ROS1-Positive NSCLC
This week, we review the U.S. Preventive Services Task Force (USPSTF) recommendation against screening for pancreatic cancer in adults with no symptoms. We also talk about the discovery of a germline mutation that has been newly associated with pancreatic cancer. Lastly, we discuss a U.S. Food and Drug Administration review which concluded a common Parkinson’s disease drug does not contribute to the development of prostate cancer.
Coverage of stories discussed this week on ascopost.com:
USPSTF Recommendation on Screening for Pancreatic Cancer in Asymptomatic Adults
Germline RABL3 Mutation May Increase Risk of Pancreatic Cancer Development
FDA Review Finds No Increased Risk of Prostate Cancer With Parkinson's Disease Treatments Containing Entacapone
This week, we review a report on the combination of ibrutinib and rituximab vs standard chemoimmunotherapy in some patients with chronic lymphocytic leukemia (CLL); a study on cancer statistics in adults aged 85 and older; and a decision from the Centers for Medicare and Medicaid Services (CMS) on coverage of chimeric antigen receptor (CAR) T-cell therapy for Medicare beneficiaries.
Coverage of stories discussed this week on ascopost.com:
Ibrutinib/Rituximab vs Standard Chemoimmunotherapy in Previously Untreated CLL
Cancer in Adults Aged 85 and Older: Rates, Screening, and Survival
CMS Finalizes Decision to Cover CAR T-Cell Therapy for Medicare Beneficiaries
This week, we review a phase II trial of erdafitinib in urothelial carcinoma with an FGFR alteration.
We also talk about a report from the World Health Organization on tobacco use worldwide.
Then, we discuss two recent FDA approvals in prostate cancer and a rare joint tumor.
Coverage of stories discussed this week on ascopost.com:
Erdafitinib in FGFR-Altered Advanced Urothelial Carcinoma
WHO Releases Report on the Global Tobacco Epidemic
FDA Approves Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer
FDA Approves Pexidartinib for Tenosynovial Giant Cell Tumor
This week, we discuss an interim analysis of the MONALEESA-7 trial of the addition of ribociclib to endocrine therapy in pre- or perimenopausal women with advanced hormone receptor–positive, HER2-negative breast cancer.
We also talk about a study that examined the relationship between the duration of chemotherapy and body mass index and the development of lymphedema in some patients with breast cancer.
Lastly, we present three recent approvals and regulatory communications from the FDA.
Coverage of stories discussed this week on ascopost.com:
Overall Survival With the Addition of Ribociclib to Endocrine Therapy in Advanced HR-Positive, HER2-Negative Breast Cancer
Neoadjuvant Chemotherapy Duration and Obesity May Be Associated With Increased Risk of Lymphedema in Some Women With Breast Cancer
FDA Approves Rituximab Biosimilar for Non-Hodgkin Lymphoma, CLL, and Autoimmune Conditions
FDA Requests Manufacturer Recall of Some Textured Breast Implants
FDA Approves Pembrolizumab for Some Patients With PD-L1–Positive Esophageal Cancer
This week, we discuss a study that found a disconnect between rates of colonoscopy and recent increases in colorectal cancer incidence in younger adults.
In addition, Dr. Kimmie Ng, of Dana-Farber Cancer Institute, offers her insights on the rising rates of colorectal cancer in young adults.
Then, we turn to a report on the relationship between androgen-deprivation therapy and rates of Alzheimer disease and dementia in elderly patients with prostate cancer.
Coverage of stories discussed this week on ascopost.com:
Rise in Early-Onset Colorectal Cancer Not Fully Aligned With Screening Trends
Association Between ADT for Prostate Cancer and Diagnosis of Alzheimer Disease or Dementia in Older Patients
This week, we discuss long-term results from an extended analysis of the National Lung Screening Trial, and Dr. James Mulshine of Rush University offers his thoughts on these findings.
We also review a report on radioactive iodine treatment for hyperthyroidism and long-term risk of death from solid cancers.
Coverage of stories discussed this week on ascopost.com:
Extended Follow-up From the National Lung Screening Trial Reported
Does Radioactive Iodine Treatment for Hyperthyroidism Increase the Risk of Cancer Mortality?
We discuss two studies on colorectal cancer that were presented at the ESMO World Congress on Gastrointestinal Cancer. We also talk about a recently published study on the prevalence of pain among cancer survivors in the U.S.
Coverage of stories discussed this week on ascopost.com:
BEACON CRC: Encorafenib/Binimetinib/Cetuximab Improves Survival in BRAF V600E–Mutated Metastatic Colorectal Cancer
REARRANGE Trial Examines Flexible Regorafenib Dosing in Refractory Metastatic Colorectal Cancer
Chronic Pain in U.S. Cancer Survivors
In this episode, The ASCO Post'sEditor-in-Chief Dr. James Armitage talks about the International Conference on Malignant Lymphoma (ICML), which he attended recently in Lugano, Switzerland; in particular, Dr. Armitage shares insight from a workshop on bridging liquid biopsy into the management of patients with lymphoma. He also discusses two studies from the plenary session looking at the impact of adding lenalidomide to R-CHOP in the management of diffuse large B-cell lymphoma.
Later in the podcast, we discuss findings from the PHARE trial on adjuvant trastuzumab dosing in HER2-positive breast cancer and we report two recent approvals by the FDA.
Coverage of stories discussed this week on ascopost.com:
Final Analysis of the PHARE Trial: 6 Months vs 12 Months of Adjuvant Trastuzumab in HER2-Positive Breast Cancer
FDA Approves Daratumumab in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed, Transplant-Ineligible Patients With Multiple Myeloma
FDA Approves Bevacizumab Biosimilar for Five Cancer Types
In this episode, we discuss news from the Annual Congress of the European Hematology Association in multiple myeloma, catch up on a study presented at ASCO on gastric cancer, and review a recently published paper on prostate cancer development in World Trade Center first responders.
Coverage of stories discussed this week on ascopost.com:
EHA 2019: CASSIOPEIA Trial Examines Addition of Daratumumab to Standard Treatment Before and After ASCT in Multiple Myeloma
Exposure to Specific Carcinogens and Prostate Cancer Risk Among World Trade Center First Responders
In this episode, we discuss more news from the ASCO Annual Meeting, including findings from a study with relevance to surgical oncology, a summary of a study in HER2-positive breast cancer, and a third study on discrimination among hem/onc fellows. We also discuss two FDA approvals which took place in the last week.
Coverage of stories discussed this week on ascopost.com:
Discrimination, Gender Bias in Oncology Training and Professional Meetings
FDA Approves New Trastuzumab Biosimilar
FDA Expands Indications for Pembrolizumab to Include Metastatic SCLC With Disease Progression on or After Other Therapies
In this episode, we discuss more news from the ASCO Annual Meeting, sharing interviews with experts on studies in pancreatic, urothelial, and cervical cancers. We’ll also tell you about a couple of new drug approvals announced this week by the FDA.
In this debut episode of The ASCO Post Podcast, experts in breast, prostate, and lung cancers and multiple myeloma provide clinical insights about selected studies presented at the recent ASCO Annual Meeting, plus news from the FDA.
To learn more, visit ascopost.com/podcasts.
For nearly a decade, The ASCO Post has been bringing you news about clinical advancements in oncology and hematology. Now, this award-winning coverage comes to you in a new format.
To learn more, visit ascopost.com/podcasts.